The Story of Influenza Antivirals: Part 18
Tamiflu licensing in the EU and the FDA-approved indications
On 18 February 2002, a committee of two EMEA (now the EMA) staff and 18 outside experts met to consider the following three questions:
Is the oseltamivir treatment of children feasible from the clinical point of view?
Is the oseltamivir treatment of adult risk groups feasible from the clinical point of view?
Is the seasonal and/or post-exposure prophylaxis…